Comparative Pharmacology
Head-to-head clinical analysis: APRESAZIDE versus HIWOLFIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APRESAZIDE versus HIWOLFIA.
APRESAZIDE vs HIWOLFIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Apresazide is a combination of hydralazine, a direct-acting vasodilator that relaxes arteriolar smooth muscle, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule.
Selective agonist at central nervous system GABA-A receptors, enhancing inhibitory neurotransmission.
1 capsule (hydralazine 25 mg / hydrochlorothiazide 25 mg) orally twice daily; may increase to 2 capsules twice daily if needed. Maximum: 4 capsules daily.
Not established; investigational agent.
None Documented
None Documented
Hydralazine: 2-4 hours (fast acetylators), 4-8 hours (slow acetylators); Hydrochlorothiazide: 6-15 hours. Clinical context: Dosing interval typically 12 hours for hydralazine component.
Terminal elimination half-life is 18 hours (range 14-22 hours). Clinically, this supports once-daily dosing in most patients; however, in renal impairment (CrCl <30 mL/min), half-life extends to 40 hours, requiring dose adjustment.
Hydralazine: ~75% renal (metabolites), <10% unchanged; Hydrochlorothiazide: >95% renal (unchanged).
Renal excretion accounts for 70% of elimination, with 30% via biliary/fecal routes. Of the renal component, 90% is eliminated unchanged, 10% as metabolites.
Category C
Category C
Antihypertensive
Antihypertensive